113 related articles for article (PubMed ID: 34046792)
21. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated With Cytotoxic Neoadjuvant Chemotherapy.
Khoury T; Nagrale V; Opyrchal M; Peng X; Wang D; Yao S
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):523-532. PubMed ID: 28187033
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic value of B lymphocyte infiltration in breast cancer].
Yu H; Yang J; Jiao S; Wang J
Nan Fang Yi Ke Da Xue Xue Bao; 2013 May; 33(5):750-5. PubMed ID: 23689000
[TBL] [Abstract][Full Text] [Related]
24. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.
Burugu S; Asleh-Aburaya K; Nielsen TO
Breast Cancer; 2017 Jan; 24(1):3-15. PubMed ID: 27138387
[TBL] [Abstract][Full Text] [Related]
25. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.
Solinas C; Garaud S; De Silva P; Boisson A; Van den Eynden G; de Wind A; Risso P; Rodrigues Vitória J; Richard F; Migliori E; Noël G; Duvillier H; Craciun L; Veys I; Awada A; Detours V; Larsimont D; Piccart-Gebhart M; Willard-Gallo K
Front Immunol; 2017; 8():1412. PubMed ID: 29163490
[TBL] [Abstract][Full Text] [Related]
27. Peri- and intratumoral T and B lymphocytic infiltration in breast cancer.
Menegaz RA; Michelin MA; Etchebehere RM; Fernandes PC; Murta EF
Eur J Gynaecol Oncol; 2008; 29(4):321-6. PubMed ID: 18714562
[TBL] [Abstract][Full Text] [Related]
28. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
29. Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast.
Tamiolakis D; Simopoulos C; Cheva A; Lambropoulou M; Kotini A; Jivannakis T; Papadopoulos N
Eur J Gynaecol Oncol; 2002; 23(5):433-6. PubMed ID: 12440819
[TBL] [Abstract][Full Text] [Related]
30. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
31. High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer.
Gatti G; Betts C; Rocha D; Nicola M; Grupe V; Ditada C; Nuñez NG; Roselli E; Araya P; Dutto J; Boffelli L; Fernández E; Coussens LM; Maccioni M
Breast Cancer Res; 2021 Mar; 23(1):40. PubMed ID: 33766090
[TBL] [Abstract][Full Text] [Related]
32. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
Terkelsen T; Russo F; Gromov P; Haakensen VD; Brunak S; Gromova I; Krogh A; Papaleo E
Breast Cancer Res; 2020 Jun; 22(1):73. PubMed ID: 32605588
[TBL] [Abstract][Full Text] [Related]
33. Impact of Breast Tumor Onset on Blood Count, Carcinoembryonic Antigen, Cancer Antigen 15-3 and Lymphoid Subpopulations Supported by Automatic Classification Approach: A Pilot Study.
Baselice S; Castaldo R; Giannatiempo R; Casaretta G; Franzese M; Salvatore M; Mirabelli P
Cancer Control; 2021; 28():10732748211048612. PubMed ID: 34620015
[TBL] [Abstract][Full Text] [Related]
34. Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer.
Verma R; Hanby AM; Horgan K; Verghese ET; Volpato M; Carter CR; Hughes TA
Breast Cancer Res Treat; 2020 Aug; 183(1):49-59. PubMed ID: 32577938
[TBL] [Abstract][Full Text] [Related]
35. Immune cell quantitation in normal breast tissue lobules with and without lobulitis.
Degnim AC; Brahmbhatt RD; Radisky DC; Hoskin TL; Stallings-Mann M; Laudenschlager M; Mansfield A; Frost MH; Murphy L; Knutson K; Visscher DW
Breast Cancer Res Treat; 2014 Apr; 144(3):539-49. PubMed ID: 24596048
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of infiltrating immune cell subtypes in invasive ductal carcinoma of the breast.
Xu Y; Lan S; Zheng Q
Tumori; 2018 Jun; 104(3):196-201. PubMed ID: 28430349
[TBL] [Abstract][Full Text] [Related]
37. Characterization and frequency distribution of lymphoreticular infiltrates in axillary lymph node metastases of invasive ductal carcinoma of the breast.
Horst HA; Horny HP
Cancer; 1987 Dec; 60(12):3001-7. PubMed ID: 2824022
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
[TBL] [Abstract][Full Text] [Related]
39. Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters.
Zabotina TN; Korotkova OV; Chertkova AI; Zakharova EN; Tabakov DV; Dzhgamadze NT; Savostikova MV; Artamonova EV; Khailenko VA; Kovalenko EI; Kadagidze ZG
Bull Exp Biol Med; 2018 Dec; 166(2):241-244. PubMed ID: 30488197
[TBL] [Abstract][Full Text] [Related]
40. Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status.
Li HN; Li XR; Lv ZT; Cai MM; Wang G; Yang ZF
Cancer Med; 2020 Dec; 9(24):9554-9570. PubMed ID: 33058542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
